New combo approach for kidney cancer shows promise in early trial
NCT ID NCT05410509
First seen Jun 27, 2026 · Last updated Jun 30, 2026 · Updated 2 times
Summary
This study tested a two-step treatment for medium-sized kidney tumors (4.1-7 cm). First, doctors blocked the tumor's blood supply, then froze it. The goal was to see if this approach is safe and works well. 25 adults with stage T1b kidney cancer took part. The main focus was on serious side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RENAL CELL CARCINOMA (RCC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Mayo Clinic
Rochester, Minnesota, 55905, United States
-
Stanford Cancer Institute
Stanford, California, 94305, United States
-
Thomas Jefferson Health
Philadelphia, Pennsylvania, 19107, United States
-
University of Alabama at Birmingham
Birmingham, Alabama, 35294, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can fasting two days a week slow kidney cancer? a new trial tests the idea
- Cell therapy combo aims to boost kidney cancer treatment
- First-in-Class cancer drug targets Hard-to-Treat tumors
- Immunotherapy after kidney cancer surgery: can a blood test predict who stays Cancer-Free?
- Engineered immune cells take on kidney cancer in first human test
- No clamps, no stitches: new robotic surgery aims to save more kidney function